People on the Move
Neostem
Neostem, which develops and manufactures proprietary and cell therapy products, has appointed David Altarac as VP of regulatory affairs. The company plans an expansion of its therapeutic pipeline expansion in 2014 and Altarac will manage the resulting increased regulatory operations.
He told Outsourcing-Pharma.com regulatory agencies play a critical role in the rapidly evolving field of adult stem cell therapies:
“These products have unique attributes that do not fit neatly into the conventional development paradigm. Our experience has been one in which regulators are receptive and supportive of exploring a new regulatory framework which will make available safe and effective cell therapies,” he continued.
Altarac moves from a 13-year career at Merck and Co, most recently as VP of regulatory affairs in emerging markets and research and development.
